• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

勘误：大黄素干扰AKT1介导的DNA损伤并降低乳腺癌细胞对多柔比星的耐药性。

Corrigendum: Emodin Interferes With AKT1-Mediated DNA Damage and Decreases Resistance of Breast Cancer Cells to Doxorubicin.

作者信息

Li Bo, Zhao Xin, Zhang Lei, Cheng Wen

机构信息

Department of Ultrasound, Harbin Medical University Cancer Hospital, Harbin, China.

Department of Orthopedics, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.

出版信息

Front Oncol. 2021 Jun 2;11:687841. doi: 10.3389/fonc.2021.687841. eCollection 2021.

DOI:10.3389/fonc.2021.687841
PMID:34150656
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8208168/
Abstract

[This corrects the article DOI: 10.3389/fonc.2020.588533.].

摘要

[本文更正了文章的数字对象标识符：10.3389/fonc.2020.588533。]

相似文献

1
Corrigendum: Emodin Interferes With AKT1-Mediated DNA Damage and Decreases Resistance of Breast Cancer Cells to Doxorubicin.勘误：大黄素干扰AKT1介导的DNA损伤并降低乳腺癌细胞对多柔比星的耐药性。
Front Oncol. 2021 Jun 2;11:687841. doi: 10.3389/fonc.2021.687841. eCollection 2021.
2
Emodin Interferes With AKT1-Mediated DNA Damage and Decreases Resistance of Breast Cancer Cells to Doxorubicin.大黄素干扰AKT1介导的DNA损伤并降低乳腺癌细胞对多柔比星的耐药性。
Front Oncol. 2021 Feb 9;10:588533. doi: 10.3389/fonc.2020.588533. eCollection 2020.
3
Retraction: Emodin interferes with AKT1-mediated DNA damage and decreases resistance of breast cancer cells to doxorubicin.撤回声明：大黄素干扰AKT1介导的DNA损伤并降低乳腺癌细胞对阿霉素的耐药性。
Front Oncol. 2023 Dec 7;13:1337635. doi: 10.3389/fonc.2023.1337635. eCollection 2023.
4
Corrigendum: STAT5a Confers Doxorubicin Resistance to Breast Cancer by Regulating ABCB1.勘误：STAT5a通过调控ABCB1赋予乳腺癌多柔比星耐药性。
Front Oncol. 2022 Mar 9;12:880458. doi: 10.3389/fonc.2022.880458. eCollection 2022.
5
Corrigendum: Somatic DNA damage response and homologous repair gene alterations and its association with tumor variant burden in breast cancer patients with occupational exposure to pesticides.勘误：职业接触农药的乳腺癌患者的体细胞DNA损伤反应和同源修复基因改变及其与肿瘤变异负担的关联
Front Oncol. 2022 Sep 23;12:1014392. doi: 10.3389/fonc.2022.1014392. eCollection 2022.
6
Corrigendum: Modulated TRPC1 Expression Predicts Sensitivity of Breast Cancer to Doxorubicin and Magnetic Field Therapy: Segue Towards a Precision Medicine Approach.勘误：TRPC1表达的调控预测乳腺癌对多柔比星和磁场疗法的敏感性：迈向精准医学方法。
Front Oncol. 2022 Apr 20;12:892408. doi: 10.3389/fonc.2022.892408. eCollection 2022.
7
Corrigendum: ITGB5 promotes innate radiation resistance in pancreatic adenocarcinoma by promoting DNA damage repair and the MEK/ERK signaling pathway.勘误：整合素β5（ITGB5）通过促进DNA损伤修复和MEK/ERK信号通路，增强胰腺腺癌的固有辐射抗性。
Front Oncol. 2024 Feb 22;14:1381151. doi: 10.3389/fonc.2024.1381151. eCollection 2024.
8
Emodin, aloe-emodin and rhein induced DNA damage and inhibited DNA repair gene expression in SCC-4 human tongue cancer cells.大黄素、芦荟大黄素和rhein 诱导 SCC-4 人舌癌细胞 DNA 损伤并抑制 DNA 修复基因的表达。
Anticancer Res. 2010 Mar;30(3):945-51.
9
Corrigendum: GZ17-6.02 and Doxorubicin Interact to Kill Sarcoma Cells Autophagy and Death Receptor Signaling.勘误：GZ17 - 6.02与多柔比星相互作用以杀死肉瘤细胞：自噬与死亡受体信号传导。
Front Oncol. 2021 Apr 16;11:677725. doi: 10.3389/fonc.2021.677725. eCollection 2021.
10
Corrigendum: ESR1 fusions and therapeutic resistance in metastatic breast cancer.勘误：转移性乳腺癌中的ESR1融合与治疗耐药性。
Front Oncol. 2023 Mar 6;13:1155540. doi: 10.3389/fonc.2023.1155540. eCollection 2023.

引用本文的文献

1
Progress on the mechanism of action of emodin against breast cancer cells.大黄素对乳腺癌细胞作用机制的研究进展
Heliyon. 2024 Oct 1;10(21):e38628. doi: 10.1016/j.heliyon.2024.e38628. eCollection 2024 Nov 15.